Fixed-dose combination
Bacitracin zinc, Neomycin and Polymyxin b is a fixed-dose combination of an aminoglycoside antibacterial and a polymyxin-class antibacterial. It is available as eye ointment for ophthalmic use. MedsAcross supplies Bacitracin zinc, Neomycin and Polymyxin b for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
Source: US FDA prescribing information
Apply the ointment topically into the conjunctival sac of the affected eye(s) every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.
Source: US FDA prescribing information
Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is contraindicated in individuals who have shown hypersensitivity to any of its components.
Source: US FDA prescribing information
NOT FOR INJECTION INTO THE EYE Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal wound healing. Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication.
Source: US FDA prescribing information
Adverse reactions have occurred with the anti-infective components of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including itching, swelling, and conjunctival erythema. More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported.
Source: US FDA prescribing information
Store between 15°C to 25°C (59°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Bacitracin zinc, Neomycin and Polymyxin b, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Neomycin and Polymyxin B Sulfates and Bacitracin Zinc 400 units/3.5 mg/10000 units per g eye ointmentOphthalmic | Bacitracin zinc, Neomycin and Polymyxin b | Bausch & Lomb | US FDA | Available on request |
1 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 10 May 1971 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Bacitracin zinc, Neomycin and Polymyxin b and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Bacitracin zinc, Neomycin and Polymyxin b, including Neomycin and Polymyxin B Sulfates and Bacitracin Zinc.
Yes. The US FDA first approved Bacitracin zinc, Neomycin and Polymyxin b on 10 May 1971, according to Drugs@FDA.
No listed presentation of Bacitracin zinc, Neomycin and Polymyxin b is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.